Poster presented at the NIDA Blending Conference, "Blending Addiction Science and Practice: Evidence-Based Treatment and Prevention in Diverse Populations and Settings," Albuquerque, NM, April 22-23, 2010.
Lirio S. Covey, PhD (Columbia University Medical Center, LI Node), Mei-Chen Hu, PhD (Columbia University Mailman School of Public Health, NY Node), Theresa M. Winhusen, PhD (University of Cincinnati/CinARC, OV Node), Judith Weissman (Weill-Cornel Medical College), Ivan Berlin, MD, PhD (Hôpital Pitié-Salpêtrière, Paris, France), Edward V. Nunes, MD (New York State Psychiatric Institute, LI Node).
Race-related variations in drug response is recognized, but scant information exists on racial/ethnic differences in responses to smoking cessation treatments or methylphenidate. This study, a secondary analysis of data from protocol CTN-0029 ("A Pilot Study of Osmotic-Release Methylphenidate in Initiating and Maintaining Abstinence in Smokers with ADHD"), aimed to explore racial/ethnic differences in: the efficacy of OROS-Methylphenidate (OROS-MPH) on smoking abstinence as a function of ADHD treatment; the efficacy of OROS-MPH on ADHD symptoms, desire to smoke, and tobacco withdrawal symptoms when added to nicotine patch and behavioral counseling; and the effects of changes in those symptoms on the abstinence rate. The study found higher abstinence rates with OROS-MPH than placebo in non-white participants, but not in whites, however OROS-MPH reduced ADHD symptoms in both populations. OROS-MPH reduced desire to smoke in non-whites only, and decrease in desire to smoke from baseline predicted continuous abstinence during weeks 7-10. Results suggest that decrease in desire to smoke mediates the treatment effect on continuous abstinence and should be tested with larger and more homogenous samples of non-whites. (Poster, PowerPoint slides, English, 2010)
Keywords: African Americans | Attention Deficit Hyperactivity Disorder (ADHD) | Concerta | CTN platform/ancillary study | Hispanics and Latinos | Minority groups | Nicotine replacement therapy | Osmotic-Release Methylphenidate (OROS-MPH) | Pharmacological therapy | Smoking | NIDA Blending Conference, 2010
Document No: 463
Submitted by Edward Nunes, MD (LI Node), 5/19/2010.